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Background
cGMP has recently been suggested to have not only pro-
tective but also proliferative and proaggregatory effects.
These may differ from nitric oxide, which can also act
independently of cGMP. sGC stimulators (which target
the reduced Fe2+ form of sGC) and activators (which target
the oxidised/heme-free state) are ideal tools to study these
as they elevate cGMP in an NO-independent manner. We
wanted to investigate the long-term effects of these com-
pounds using the sGC stimulator, BAY 41-2272, and the
activator, BAY 58-2667, in aged spontaneously hyperten-
sive rats (SHR). This model of advanced cardiovascular
disease exhibits marked cardiac hypertrophy and fibrosis.
Methods
Aged SHR (20–22 months) were treated for 4 weeks with
BAY 41-2272 (1 mg/kg/day, i.p.) or BAY 58-2667 (0.3 mg
or 1 mg/kg/day, i.p.). Mean arterial pressure (MAP) was
measured by radiotelemetry and heart:body weight ratio
and cardiac fibrosis (0.001% Picrosirius red) were deter-
mined as indicators of cardiac remodelling.
Results
MAP was transiently reduced after i.p. injections but basal
MAP, measured ~8 hr after injection, remained stable
throughout the entire study and was not significantly
influenced by drug treatments. Both BAY 41-2272 and
BAY 58-2667 dramatically decreased indices of cardiac
remodelling such that fibrosis levels were reduced to that
of age-matched normotensive Wistar-Kyoto rats (WKY).
Cardiac interstitial collagen content (%) under BAY 41-
2272 was 7.0 ± 0.3 (n = 8, P < 0.01 versus vehicle-treated
SHR); the high dose of BAY 58-2667, 6.7 ± 0.2 (n = 9, p <
0.001 versus vehicle-treated SHR); vehicle-treated SHR,
9.0 ± 0.5 (n = 10); vehicle-treated WKY, 6.0 ± 0.2 (n = 7).
Similarly, marked reductions in heart weight: body weight
(mg/g) were observed: BAY 41-2272, 4.6 ± 0.2; high dose
BAY 58-2667, 5.0 ± 0.2; vehicle-treated SHR, 5.9 ± 0.3;
vehicle-treated WKY, 3.5 ± 0.03.
Conclusion
In this model of advanced cardiovascular disease due to
aging and hypertension, BAY 41-2272 or BAY 58-2667
rapidly reverses pathological cardiac changes that are
already established. Such antihypertrophic and antifi-
brotic effects occurred without a sustained antihyperten-
sive effect, and indicate that sGC is a valid target for
cardioprotection.
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